Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership NATIONAL & QUEBEC CLASS | WebDisclosure

Switch to English

9472	Sociétés
185370	Mots-clés
117721	Articles
99262	Communiqués

À la une Tous les articles Tous les communiqués Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership NATIONAL & QUEBEC CLASS

Accueil
Sociétés
Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership NATIONAL & QUEBEC CLASS

BRÈVE

publiée le 23/02/2024 à 21:30, il y a 1 année 9 mois

Successful Initial Closing for Maple Leaf Critical Minerals with Attractive Tax Prospects

Investment Canada Maple Leaf Critical Minerals Tax Deductions Diversified Portfolio
COMMUNIQUÉ DE PRESSE

publié le 23/02/2024 à 21:30, il y a 1 année 9 mois

$16,620,625 Raised on Initial Closing. Books Now Re-Open for a Final Closing on April 12, 2024
Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership announces the completion of its initial closing, offering tax benefits and diversified portfolios for National & Québec Class Units

Investment Flow-through Shares Canada Maple Leaf Critical Minerals Tax Benefits
COMMUNIQUÉ DE PRESSE

publié le 13/02/2024 à 14:40, il y a 1 année 9 mois

Final Prospectus Filed-Books Closing February 22, 2024 for Initial Closing
Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership files final prospectus for initial public offering of units with tax benefits for investors. Active management for liquidity event potential. Syndicate led by Scotia Capital Inc. Full details in Prospectus

Enhanced Flow-Through Limited Partnership Maple Leaf Critical Minerals Tax Benefits Syndicate Liquidity Event
COMMUNIQUÉ DE PRESSE

publié le 16/12/2023 à 00:05, il y a 1 année 11 mois

Preliminary Prospectus Filed - Maple Leaf Critical Minerals 2024 Enhanced Flow-Through Limited Partnership NATIONAL & QUEBEC CLASS

Les Echos

Publié le 04/12/2025 à 18:14, il y a 13 heures 37 minutes

Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 51 minutes

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 51 minutes

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 6 minutes

Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 6 minutes

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/12/2025 à 02:35, il y a 5 heures 16 minutes

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 02:30, il y a 5 heures 21 minutes

Klondike Gold Announces AGM Results
Publié le 05/12/2025 à 01:00, il y a 6 heures 51 minutes

BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 46 minutes

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 51 minutes

NXT Energy Solutions Completes Data Acquisition for SFD Survey

Voir tout ACCESSWIRE

EQS Group

Publié le 05/12/2025 à 07:00, il y a 51 minutes

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 21 minutes

CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 8 heures 1 minute

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 26 minutes

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 36 minutes

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025